Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
T C SheaR Taetle

Abstract

To examine the ability of carboplatin to mobilize peripheral-blood progenitor cells (PBPCs) and to examine the impact of infusing these cells on myelosuppression following multiple cycles of high-dose therapy. Fluctuations in circulating progenitor cell concentration following repeated cycles of this therapy were also measured. Eight patients received a total of 20 cycles of carboplatin 1,200 mg/m2 per course, granulocyte-macrophage colony-stimulating factor (GM-CSF) 5 micrograms/kg/d, and PBPC reinfusion every 28 days. PBPC were collected following 1 week of GM-CSF and following the first and second cycles of chemotherapy. Hematologic toxicity was correlated with the number of progenitor cells reinfused per cycle. The concentration of PBPC per milliliter of blood was measured at study entry, following GM-CSF priming, and after each cycle of chemotherapy. We observed a strong inverse correlation between the number of PBPCs (CD34 and colony-forming unit granulocyte-macrophage [CFU-GM]), but not mononuclear cells (MNCs) reinfused and the days with neutropenia less than 500/microL and platelets less than 20,000/microL. Compared with baseline levels, the circulating PBPC concentration increased up to 27-fold following the first cou...Continue Reading

Citations

Jan 1, 1997·Cancer Investigation·J R Mason, A D Ho
Sep 12, 2000·Journal of Hematotherapy & Stem Cell Research·A MillerR Weiner
Jun 1, 1996·Medical Oncology·M HanssonP Engervall

❮ Previous
Next ❯

Related Concepts

Related Papers

Acta Obstetricia Et Gynecologica Scandinavica
Hitoshi KurataKenichi Tanaka
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R J SchilderR F Ozols
© 2021 Meta ULC. All rights reserved